Genes Cancer 2011, 2:420–430.PubMedCrossRef 26. Vlahos NF, Economopoulos KP, Fotiou S: Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. Best Pract Res Clin Obstet Gynaecol 2010, 24:39–50.PubMedCrossRef 27. IeM S, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164:1511–1518.CrossRef 28. Ho CL, Kurman RJ, Dehari R, Wang TL, selleckchem Shih IM: Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004, 64:6915–6918.PubMedCrossRef 29. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, Choong DY, Campbell IG: High-Resolution single nucleotide
polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res 2007, 13:4731–4739.PubMedCrossRef 30. Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC: Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns inmucinous ovarian and appendiceal carcinomas. Clin
Cancer Res 2005, 11:7651–7657.PubMedCrossRef 31. Matsuo K, EX 527 Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK: Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res 2011, 17:5367–5378.PubMedCrossRef 32. Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA: Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 2011, 117:554–562.PubMedCrossRef 33. Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart
AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A: Gynecologic Cancer Interleukin-2 receptor InterGroup: Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Selleck MK5108 Gynecol Cancer 2010, 20:945–952.PubMedCrossRef 34. Niyazi M, Ghazizadeh M, Konishi H, Kawanami O, Sugisaki Y, Araki T: Expression of p73 and c-Abl proteins in human ovarian carcinomas. Nippon Med Sch 2003, 70:234–242.CrossRef 35. Emons G, Kavanagh JJ: Hormonal interactions in ovarian cancer. Hematol Oncol Clin North Am 1999, 13:145–161.PubMedCrossRef 36. Murdoch WJ, Van Kirk EA, Isaak DD, Shen Y: Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts. Gynecol Onco 2008, 110:251–255.CrossRef 37. Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O: Hormone therapy and ovarian cancer. JAMA 2009, 302:298–305.PubMedCrossRef 38. Beral V, Bull D, Green J, Reeves G, Million Women Study Collaborators: Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007, 369:1703–1710.